Abstract Polo-like kinase 1 (PLK1) plays an important role in the initiation, maintenance, and
completion of mitosis. Dysfunction of PLK1 may promote cancerous transformation and drive …

Polo-like kinase I (PLK1), a cell cycle regulating kinase, has been shown to have oncogenic
function in several cancers. Although PLK1 inhibitors, such as BI2536, BI6727 (volasertib) …

Multidrug resistance is the most widely exploited phenomenon by which cancer eludes
chemotherapy. Broad variety of factors, ranging from the cellular ones, such as over …

Initially regarded as “epigenetic modifiers” acting predominantly through chromatin
remodeling via histone acetylation, HDACIs, alternatively referred to as lysine deacetylase …

Current microtubule-targeting agents (MTAs) remain amongst the most important antimitotic
drugs used against a broad range of malignancies. By perturbing spindle assembly, MTAs …

Abstract Polo-like kinase 1 (PLK1) is a conserved mitotic serine-threonine protein kinase,
functions as a regulatory protein, and is involved in the progression of the mitotic cycle. It …

Myeloproliferative neoplasms (MPNs) feature a malignant clone containing the JAK2 V617F
mutation, or another mutation causing dysregulated JAK2 kinase activity. The multiple …

The approval of histone deacetylase inhibitors for treatment of lymphoma subtypes has
positioned histone modifications as potential targets for the development of new classes of …

Cancer cells usually display higher proliferation rates than normal cells. Some currently
used antitumor drugs, such as vinca alkaloids and taxanes, act by targeting microtubules …

Abstract Trastuzumab-refractory, HER2 (human epidermal growth factor receptor 2)-positive
breast cancer is commonly treated with trastuzumab emtansine (T-DM1), an antibody–drug …